Drug intelligence / Profile preview

GDA-601

Development stage: Discontinued
Lead developer: Gamida Cell
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GDA-601 is an investigational, nicotinamide-enabled, genetically engineered natural killer (NK) cell therapy designed for multiple myeloma that combines CRISPR/Cas9 knockout of CD38 to prevent NK cell fratricide with an anti-CD38 chimeric antigen receptor (CAR) to enhance recognition and killing of CD38-positive myeloma cells. Preclinical data show reduced CD38-mediated fratricide, increased degranulation (CD107a), and elevated proinflammatory cytokines with enhanced cytotoxicity against multiple myeloma cell lines; the program is being advanced in collaboration with Dana-Farber Cancer Institute. The platform uses Gamida Cell’s NAM expansion to improve NK cell functionality, including cytotoxicity, resistance to exhaustion, oxidative stress protection, and homing properties.

Other names: GDA 601GDA601GDA-601

Targets

CD38 (Cluster of Differentiation 38)

Beyond the preview

Go deeper on GDA-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GDA-601.

Explore the full profile